Latest Research
All publications from the Cancer3.AI database, newest first.
Covalent modification of Keap1 Cys489 by NU6300 activates Nrf2 signaling and suppresses NLRP3 inflammasome-mediated pyroptosis.
Jiang X, et al
Researchers identified NU6300 as a novel small-molecule activator of the Nrf2 protein, a master regulator of oxidative stress and inflammation in cells. The compound works by covalently binding to a specific site on the Keap1 protein (cysteine-489), which normally keeps Nrf2 inactive, thereby freeing Nrf2 to enter the cell nucleus and switch on protective antioxidant genes. Critically, NU6300 also blocks the NLRP3 inflammasome and a form of inflammatory cell death called pyroptosis, representing the first direct mechanistic link between Keap1 cysteine-489 modification and inflammasome suppression. In mouse models, NU6300 provided strong protection against acetaminophen-induced acute liver injury, a clinically relevant condition with limited treatment options. These findings position NU6300 as a promising therapeutic candidate for a broad range of inflammatory and pyroptosis-driven diseases, including drug-induced liver injury.
Journal of pharmaceutical analysis
Source →Perineural Invasion in Head and Neck Malignancies: Clinical, Radiological and Pathological Correlation.
Ganga VB, et al
A retrospective study published in the Journal of Maxillofacial and Oral Surgery examined perineural invasion (PNI) — the spread of cancer cells along nerve sheaths — across 216 patients treated for head and neck malignancies between 2016 and 2019, assessing how frequently this feature was detected by imaging versus confirmed by tissue pathology. Oral cavity squamous cell carcinoma was the most common cancer type (61%), but salivary gland tumors and maxillary tumors showed the highest rates of PNI, with pathological confirmation in 80% and 57.1% of cases respectively. A statistically significant association was found between tumor location and PNI detection rates (p<0.001), revealing that current imaging identifies PNI far less reliably in some subsites — for instance, radiological detection in laryngeal tumors reached only 11.1% while pathological confirmation stood at 28.9%. These discrepancies highlight a critical diagnostic gap: patients whose PNI is missed on imaging may receive inadequate treatment planning, since PNI is associated with worse survival and typically warrants more aggressive therapy such as adjuvant radiotherapy. The authors conclude that improved imaging protocols and deeper molecular understanding of PNI are urgently needed to close this gap and explore PNI as a potential therapeutic target.
Journal of maxillofacial and oral surgery
Source →Oculoplastics and Augmented Intelligence: A Literature Review.
Ing E, et al
A new literature review published in the Journal of Clinical Medicine examines the current and emerging applications of artificial intelligence in oculoplastic surgery, a subspecialty of ophthalmology focused on the eyelids, orbit, and lacrimal system. Researchers surveyed AI tools being developed for conditions including ptosis (drooping eyelids), eyelid and conjunctival cancers, thyroid-associated orbitopathy, giant cell arteritis, and orbital fractures, finding that AI can meaningfully assist with screening, diagnosis, and predicting surgical outcomes. The review also highlights the potential of large language models such as ChatGPT to support patient counseling, while noting that further validation is required before such tools can be trusted for clinical use. Privacy risks associated with facial and ocular image data were identified as a significant challenge, with blockchain technology, federated learning, and steganography proposed as protective solutions. The authors emphasize that large, well-validated datasets are essential for developing reliable AI systems in this field. Overall, the review concludes that AI should serve as an augmentative tool that enhances, rather than replaces, the judgment and expertise of trained physicians.
Journal of clinical medicine
Source →Primary Aggressive Oral Lymphomas (PAOL): A Narrative Review of Diagnosis, Molecular Features, Therapeutic Approaches, and the Integrated Role of Dentists and Hematologists.
Bibas M, et al
A new narrative review published in the journal Cancers examines primary aggressive oral lymphomas (PAOL), a rare group of cancers arising in the mouth that account for only 2-3% of all lymphomas. These malignancies, most commonly diffuse large B-cell lymphoma and plasmablastic lymphoma, frequently mimic benign dental problems such as swelling, pain, or tooth mobility, causing dangerous delays in diagnosis. The review emphasizes that accurate identification requires a combined approach involving thorough oral examination, advanced imaging (CT, MRI, PET-scan), tissue biopsy, and molecular genetic testing. Treatment relies primarily on systemic chemotherapy, with rituximab added for CD20-positive tumors and radiotherapy used in localized cases, while patients with HIV or organ transplants often need individualized strategies due to viral co-infections such as EBV and HHV-8. The authors highlight the dentist's crucial and often underappreciated role: not only in early detection but also in supporting patients throughout cancer treatment and monitoring for recurrence and long-term side effects afterward. This comprehensive overview underscores the need for close collaboration between dentists and hematologists to improve outcomes for patients with these aggressive and diagnostically challenging oral cancers.
Cancers
Source →Conjunctival Melanoma: Current Management.
Krema H
A comprehensive review published in International Ophthalmology Clinics examines the current management strategies for conjunctival melanoma, a rare but potentially deadly cancer primarily affecting fair-skinned individuals and most commonly arising from a precancerous condition called primary acquired melanosis with atypia. The review highlights that genetic mutations in BRAF, NRAS, and NF1 genes are associated with worse patient survival, and that ultraviolet light exposure plays a significant role in the development of this cancer on the surface of the eye. Treatment approaches are tailored to tumor stage and location, ranging from surgical excision using specialized no-tumor-touch techniques combined with cryotherapy for localized disease, to various forms of radiotherapy and topical chemotherapy for more diffuse or advanced cases. For metastatic or extensive disease, modern systemic therapies including BRAF-targeted inhibitors and immunotherapy drugs have recently been introduced, mirroring advances seen in skin melanoma treatment. Clinicians are cautioned that incisional biopsy must be avoided as it can spread tumor cells and worsen outcomes, and that key risk factors for metastasis include tumor thickness, non-bulbar location, and high mitotic activity. This review provides an important clinical roadmap for ophthalmologists and oncologists managing this challenging malignancy.
International ophthalmology clinics
Source →